二大于一：联合 IGF1R 和 MEK 阻断作为一种有前途的治疗 KRAS 突变型肺癌的新策略。
Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer.
机构信息
Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
出版信息
Cancer Discov. 2013 May;3(5):491-3. doi: 10.1158/2159-8290.CD-13-0128.
Abstract
A small-molecule inhibitor screen on a panel of human lung cancer cell lines has uncovered an unexpected sensitivity of cells expressing oncogenic KRAS toward insulin-like growth factor 1 receptor (IGF1R) inhibition. Combining IGF1R and MAP-ERK kinase blockade led to significant effects on viability in human non-small cell lung cancer (NSCLC) cell lines and in 2 mouse models of oncogenic KRAS-driven lung cancer. The mechanistic basis for this effect seems to be an increased baseline activation of IGF1R-mediated activation of AKT in cells that express oncogenic KRAS. The studies thus point to a novel approach for treatment of KRAS-driven NSCLC, a particularly difficult subset of patients to treat with existing approaches.
摘要
在一组人类肺癌细胞系的小分子抑制剂筛选中，出人意料地发现表达致癌 KRAS 的细胞对胰岛素样生长因子 1 受体 (IGF1R) 抑制敏感。联合 IGF1R 和 MAP-ERK 激酶阻断导致人类非小细胞肺癌 (NSCLC) 细胞系和 2 种致癌 KRAS 驱动的肺癌小鼠模型中的细胞活力有显著影响。这种效应的机制基础似乎是表达致癌 KRAS 的细胞中 IGF1R 介导的 AKT 激活的基线活性增加。因此，这些研究为治疗 KRAS 驱动的 NSCLC 提供了一种新的方法，这是现有方法治疗特别困难的患者亚群。
相似文献
1
Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer.二大于一：联合 IGF1R 和 MEK 阻断作为一种有前途的治疗 KRAS 突变型肺癌的新策略。
Cancer Discov. 2013 May;3(5):491-3. doi: 10.1158/2159-8290.CD-13-0128.
2
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.协调 KRAS 和 IGF1 受体的直接输入，以激活 KRAS 突变型肺癌中的 PI3 激酶。
Cancer Discov. 2013 May;3(5):548-63. doi: 10.1158/2159-8290.CD-12-0446. Epub 2013 Mar 1.
3
Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.致癌性 KRAS 诱导的表皮调节素过表达有助于侵袭表型，是一种有前景的非小细胞肺癌治疗靶点。
Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.
4
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.BYL719，一种磷酸肌醇3激酶α的选择性抑制剂，增强了司美替尼（AZD6244，ARRY-142886）在KRAS突变型非小细胞肺癌中的疗效。
Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25.
5
Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.激活的cMET和IGF1R驱动的PI3K信号通路预示着结直肠癌患者的不良生存，且与KRAS突变状态无关。
PLoS One. 2014 Aug 4;9(8):e103551. doi: 10.1371/journal.pone.0103551. eCollection 2014.
6
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.阿托伐他汀克服 KRAS 突变型人非小细胞肺癌细胞中的吉非替尼耐药性。
Cell Death Dis. 2013 Sep 26;4(9):e814. doi: 10.1038/cddis.2013.312.
7
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.开发联合疗法以最大限度地提高肺癌中 KRAS-G12C 抑制剂的疗效。
Sci Transl Med. 2019 Sep 18;11(510). doi: 10.1126/scitranslmed.aaw7999.
8
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.PIK3CA 突变使肿瘤生长和细胞周期蛋白 D1 的调节与 MEK/ERK 和突变 KRAS 信号脱耦。
Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409. Epub 2010 Aug 10.
9
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.PI3K/AKT 通路通过去乙酰化酶依赖的机制促进突变型 KRAS 肺腺癌对吉非替尼的耐药性。
Int J Cancer. 2014 Jun 1;134(11):2560-71. doi: 10.1002/ijc.28594. Epub 2013 Dec 13.
10
KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.KRAS（G12D）和BRAF（V600E）诱导的小鼠胰腺上皮细胞转化需要MEK/ERK刺激的IGF1R信号传导。
Mol Cancer Res. 2012 Sep;10(9):1228-39. doi: 10.1158/1541-7786.MCR-12-0340-T. Epub 2012 Aug 7.
引用本文的文献
1
Emerging strategies to target RAS signaling in human cancer therapy.靶向人类癌症治疗中 RAS 信号的新兴策略。
J Hematol Oncol. 2021 Jul 23;14(1):116. doi: 10.1186/s13045-021-01127-w.
2
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors.靶向肿瘤微环境：一种针对KRAS突变肿瘤的未被探索的策略。
Cancers (Basel). 2019 Dec 13;11(12):2010. doi: 10.3390/cancers11122010.
3
Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.胰岛素样生长因子-2 和雄激素受体作为三阴性乳腺癌的治疗靶点。
Int J Mol Sci. 2017 Nov 2;18(11):2305. doi: 10.3390/ijms18112305.
4
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.非小细胞肺癌精准医学的基因组分析：超越表皮生长因子受体
Pharmgenomics Pers Med. 2015 Feb 20;8:63-79. doi: 10.2147/PGPM.S52845. eCollection 2015.
5
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.一项使用抗IGF-1R抗体西妥昔单抗和MEK 1/2抑制剂司美替尼对晚期实体瘤进行IGF信号通路垂直抑制的I期试验。
Br J Cancer. 2015 Jan 6;112(1):24-31. doi: 10.1038/bjc.2014.515. Epub 2014 Sep 30.
本文引用的文献
1
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.协调 KRAS 和 IGF1 受体的直接输入，以激活 KRAS 突变型肺癌中的 PI3 激酶。
Cancer Discov. 2013 May;3(5):548-63. doi: 10.1158/2159-8290.CD-12-0446. Epub 2013 Mar 1.
2
The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.GATA2 转录网络是 RAS 癌基因驱动的非小细胞肺癌所必需的。
Cell. 2012 Apr 27;149(3):642-55. doi: 10.1016/j.cell.2012.02.059.
3
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.TAK1 抑制促进 KRAS 依赖性结肠癌细胞凋亡。
Cell. 2012 Feb 17;148(4):639-50. doi: 10.1016/j.cell.2011.12.033.
4
The insulin and insulin-like growth factor receptor family in neoplasia: an update.肿瘤中胰岛素和胰岛素样生长因子受体家族：更新。
Nat Rev Cancer. 2012 Feb 16;12(3):159-69. doi: 10.1038/nrc3215.
5
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.KRAS 癌基因取代对蛋白质行为的影响：对信号转导和临床结果的影响。
J Natl Cancer Inst. 2012 Feb 8;104(3):228-39. doi: 10.1093/jnci/djr523. Epub 2012 Jan 13.
6
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.Wilms 肿瘤 1 基因（WT1）调节 KRAS 驱动的肿瘤发生和衰老在小鼠和人类模型中。
J Clin Invest. 2010 Nov;120(11):3940-52. doi: 10.1172/JCI44165. Epub 2010 Oct 25.
7
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.K-Ras 癌基因与 Cdk4 的合成致死相互作用揭示了非小细胞肺癌的治疗策略。
Cancer Cell. 2010 Jul 13;18(1):63-73. doi: 10.1016/j.ccr.2010.05.025.
8
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.系统性RNA干扰显示，致癌性KRAS驱动的癌症需要TBK1。
Nature. 2009 Nov 5;462(7269):108-12. doi: 10.1038/nature08460. Epub 2009 Oct 21.
9
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.一项全基因组RNA干扰筛选鉴定出了与Ras癌基因的多种合成致死相互作用。
Cell. 2009 May 29;137(5):835-48. doi: 10.1016/j.cell.2009.05.006.
10
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.有效使用PI3K和MEK抑制剂治疗携带Kras G12D突变和PIK3CA H1047R突变的小鼠肺癌。
Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.
Zotero 插件